Kite Pharmaceuticals Submits Application for New Lymphoma Therapy

Are these high prices justified? England health officials have come to the conclusion that a price of $649,000 for CAR-T to treat childhood leukemia is acceptable due to how much more time the treatment will offer its patients.

Some trust Gilead to offer taxpayers fair prices in response to their funding the research, while others are wary that they'll make off with a high profit at the expense of those who enabled the product to make it to market.

References

https://lymphomanewstoday.com/2017/08/03/kite-seeks-e-u-approval-car-t-cell-therapy-3-lymphoma-subtypes/

http://ir.kitepharma.com/releasedetail.cfm?releaseid=1035076

http://www.fiercepharma.com/pharma/how-will-gilead-price-car-t-execs-aren-t-saying-much-but-say-innovation-will-support-very